An FDA advisory committee approved moving six of seven “gray market” peptide compounds off the FDA’s CAT2 designation and onto the 503A bulk substance list, according to the committee’s vote and the evidence presented during a two-day meeting. The action would allow state-licensed physicians and pharmacists to compound and prescribe the peptide products. The committee decision ran counter to FDA expert recommendations to disallow all seven compounds based on current scientific evidence, including concerns about characterization gaps, limited safety information, immunogenicity and contamination risks, and insufficient clinical data. The peptides have been marketed alongside DIY injectables amid expanding interest fueled by GLP-1-related demand. Backlash focused on potential conflicts of interest, with six of 14 panelists reporting ties to private peptide clinics; those associated with peptide therapies voted to pass or abstained across the compounds considered. The FDA has not approved any products; the vote affects only the intermediate step of moving substances into a compounding category.